Deutsche Bank analyst George Hill maintained a Hold rating on Humana (HUM – Research Report) today and set a price target of $250.00. The company’s shares closed yesterday at $246.49.
According to TipRanks, Hill is a 5-star analyst with an average return of 8.8% and a 53.71% success rate. Hill covers the Healthcare sector, focusing on stocks such as R1 RCM, Cardinal Health, and CVS Health.
In addition to Deutsche Bank , Humana also received a Hold from Truist Financial’s Jailendra Singh in a report issued today. However, on the same day, Oppenheimer maintained a Buy rating on Humana (NYSE: HUM).
HUM market cap is currently $29.68B and has a P/E ratio of 17.57.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Humana (HUM) Company Description:
Humana Inc. is a leading health insurance service provider in the United States. The company, through its Retail division, provides medicare benefits and state-based medicaid contracts, which are marketed on a retail basis to individuals. The Group and Specialty business offers employer group commercial fully-insured medical products and specialty health insurance benefits. Humana offers pharmacy solutions, provider services, home-based services, and clinical programs to the company’s health plan members as well as to third parties through the Healthcare Services segment.
Read More on HUM:
- Humana downgraded to Underperform from Neutral at BofA
- Humana downgraded to Underperform at BofA after loss of leading Star position
- BofA double downgrades Agilon Health to Underperform on impaired visibility
- Humana falls -17.6%
- Baird sees ‘material’ EPS headwind for Humana on ‘worst case’ Star scenario
